Details
Stereochemistry | ACHIRAL |
Molecular Formula | C34H47NO4.C4H4O4 |
Molecular Weight | 649.8134 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.CCCCN(CCCC)CCCC1=CC=C(C=C1)C(=O)C2=C(CCCC)OC3=C2C=C(C=C3)C(=O)OC(C)C
InChI
InChIKey=OJGUHVXJDZPQSK-WLHGVMLRSA-N
InChI=1S/C34H47NO4.C4H4O4/c1-6-9-14-31-32(29-24-28(19-20-30(29)39-31)34(37)38-25(4)5)33(36)27-17-15-26(16-18-27)13-12-23-35(21-10-7-2)22-11-8-3;5-3(6)1-2-4(7)8/h15-20,24-25H,6-14,21-23H2,1-5H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
Molecular Formula | C34H47NO4 |
Molecular Weight | 533.7413 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C4H4O4 |
Molecular Weight | 116.0722 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Celivarone is a benzofuran derivative with a multifactorial mode of action including class IV Vaughan Williams’ electrophysiological as well as anti-adrenergic properties. It has no iodine and has a limited tissue accumulation compared with amiodarone. Celivarone exhibits effective anti-arrhythmic properties in several ventricular ischemia- or reperfusioninduced arrhythmia models as well as in in vitro and in vivo atrial fibrillation (AF) models. Its electrophysiological properties are similar to amiodarone (multifactorial mode of action) but with different relative effects on the ion channels. At the ventricular level, celivarone shows anti-arrhythmic activities by suppressing reperfusion-induced arrhythmias (i.v. and oral routes) and reducing the early mortality due to myocardial infarction (oral route) in rats models. At the atrial level, celivarone is effective in atrial fibrillation models with restoration of sinus rhythm or prevention of AF induction and AF recurrence.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21978965
100 or 300 mg once daily for 6 months
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:41:24 GMT 2023
by
admin
on
Fri Dec 15 15:41:24 GMT 2023
|
Record UNII |
GA9K2RD7NJ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
GA9K2RD7NJ
Created by
admin on Fri Dec 15 15:41:25 GMT 2023 , Edited by admin on Fri Dec 15 15:41:25 GMT 2023
|
PRIMARY | |||
|
401925-44-8
Created by
admin on Fri Dec 15 15:41:25 GMT 2023 , Edited by admin on Fri Dec 15 15:41:25 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
752253-75-1
Created by
admin on Fri Dec 15 15:41:25 GMT 2023 , Edited by admin on Fri Dec 15 15:41:25 GMT 2023
|
PRIMARY | |||
|
9852525
Created by
admin on Fri Dec 15 15:41:25 GMT 2023 , Edited by admin on Fri Dec 15 15:41:25 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |